Cargando…
Eltrombopag-Induced Thrombocytosis and Thrombosis in Patients With Antiphospholipid Syndrome and Immune Thrombocytopenic Purpura
Antiphospholipid syndrome (APS) may be either as a primary or in association with an underlying systemic autoimmune etiology (36.2%), particularly systemic lupus erythematosus (SLE). Thrombocytopenia is infrequently observed in APS patients, with an occurrence of 22% to 42% with the frequency of thr...
Autores principales: | Oo, Zayar, Manvar, Kapilkumar, Wang, Jen Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922183/ https://www.ncbi.nlm.nih.gov/pubmed/35277086 http://dx.doi.org/10.1177/23247096211060581 |
Ejemplares similares
-
Eltrombopag Dose Adjustment During Infection-Induced Thrombocytosis in a Patient With Chronic Idiopathic Thrombocytopenic Purpura
por: Ahmed, Mohanad, et al.
Publicado: (2021) -
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Rice, Lawrence
Publicado: (2009) -
Catastrophic Antiphospholipid Syndrome in Immune Thrombocytopenic Purpura – Beyond Tenuous Concomitance!
por: Joshi, Arun, et al.
Publicado: (2020) -
Presumed antiphospholipid syndrome and thrombotic thrombocytopenic purpura: An infrequent association
por: Dolin, Hallie Hanna, et al.
Publicado: (2019) -
Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
por: Uğur, Mehmet Can, et al.
Publicado: (2021)